CMV Vaccine Clinical Trial

CMV Vaccine Clinical Trial

What is CMV?

Cytomegalovirus (CMV) is a virus that is the most common cause of congenital viral infection in the developed world. The virus is spread through close or intimate contact with persons excreting the CMV virus, blood transfusions, breast milk, sexual intercourse and transplanted organs.

Healthy people with the CMV virus may not have any symptoms, if symptoms are present, they may mild and confused with other illnesses. Symptoms can include fever, sore throat, fatigue and swollen glands. After infection, the virus cam lay dormant for many years.
Approximately 4 million live births in the United States alone will be infected prenatally with CMV by women who have the CMV virus. At least 15% will develop symptoms of central nervous system damage either at birth or progressively in the first few months of life (such as hearing loss, mental retardation, and cerebral palsy). CMV occurs more frequently than Down Syndrome, Spina Bifida and Fetal Alcohol Syndrome.

A CMV vaccine is being developed for the prevention of infection and disease caused by CMV. To date there is no effective CMV vaccine to protect women from acquiring CMV or any recognized intervention that can effectively reduce the transmission of CMV from newly infected women to the fetus.

Compensation is available for time and travel reimbursement.

Take the next step, call us at (757) 627-6798 , and ask for Study Recruitment, better yet, fill out the brief form below and we will contact you, to see if you qualify for a promising Clinical Research Study at Clinical Research Associates of Tidewater!